Nanoviricides Inc (NNVC)

1.54
0.12 8.45
AMEX : Health Care
Prev Close 1.42
Open 1.40
Day Low/High 1.40 / 1.58
52 Wk Low/High 0.89 / 3.44
Volume 457.10K
Avg Volume 91.30K
Exchange AMEX
Shares Outstanding 63.07M
Market Cap 89.56M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest Moves 11% Lower For NNVC

Short Interest Moves 11% Lower For NNVC

The most recent short interest data has been released by the NASDAQ for the 06/15/2015 settlement date, which shows a 291,999 share decrease in total short interest for NanoViricides Inc , to 2,357,916, a decrease of 11.02% since 05/29/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

NanoViricides Stock Sees Short Interest Move 11.4% Lower

NanoViricides Stock Sees Short Interest Move 11.4% Lower

The most recent short interest data has been released by the NASDAQ for the 12/31/2014 settlement date, which shows a 346,755 share decrease in total short interest for NanoViricides Inc , to 2,701,209, a decrease of 11.38% since 12/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

NanoViricides Says Injectable FluCide™ Selected In Top Ten Project To Watch - Presentation Today At The Therapeutics Area Partnerships Meeting In Boston

NanoViricides Says Injectable FluCide™ Selected In Top Ten Project To Watch - Presentation Today At The Therapeutics Area Partnerships Meeting In Boston

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), announced today that its "Injectable FluCide™" drug candidate for severe influenza has been chosen as one of the "Top Ten Infectious Diseases Projects...

NanoViricides CEO, Eugene Seymour, MD, MPH, Invited To Discuss The Current Ebola Outbreak On Fox Business News At 9PM EDT Tonight

NanoViricides CEO, Eugene Seymour, MD, MPH, Invited To Discuss The Current Ebola Outbreak On Fox Business News At 9PM EDT Tonight

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH, has been invited to discuss the current Ebola outbreak and the...

NanoViricides, Inc. Files Quarterly Report - Reports Further Improved Strong Cash Position Sufficient For Clinical Trials Of Its First Two Drug Candidates

NanoViricides, Inc. Files Quarterly Report - Reports Further Improved Strong Cash Position Sufficient For Clinical Trials Of Its First Two Drug Candidates

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), has filed its quarterly report with the Securities and Exchange Commission on Friday, November 14th, in a timely fashion.

NanoViricides, Inc. Signs CRADA For Material Transfer With USAMRIID For Evaluating Its Anti-Ebola Drug Candidates

NanoViricides, Inc. Signs CRADA For Material Transfer With USAMRIID For Evaluating Its Anti-Ebola Drug Candidates

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, announced today that it has executed a CRADA (Collaborative Research and Development Agreement for Material...

NNVC: Insiders vs. Shorts

NNVC: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 09/30/2014 settlement date, and NanoViricides Inc is one of the most shorted stocks of the Russell 3000, based on 18.69 "days to cover" versus the median component at 6.09. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

NanoViricides CEO, Eugene Seymour, MD, MPH, Invited To Discuss The Current Ebola Outbreak On Fox Business News At 9PM EDT Tonight

NanoViricides CEO, Eugene Seymour, MD, MPH, Invited To Discuss The Current Ebola Outbreak On Fox Business News At 9PM EDT Tonight

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”), a nanomedicine company developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH, has been invited to discuss the current Ebola...

Why You Should Stay Away From the Ebola Frenzy in Biotech Stocks

Why You Should Stay Away From the Ebola Frenzy in Biotech Stocks

Ebola lands in Texas, so expect some crazy volatility Wednesday in biotech and drug stocks.

NanoViricides Reports FluCide™ Samples Were Shipped To BASi For Start Of Safety/Toxicology Studies; Also Reports That Ebola Drug Candidates Are Being Synthesized

NanoViricides Reports FluCide™ Samples Were Shipped To BASi For Start Of Safety/Toxicology Studies; Also Reports That Ebola Drug Candidates Are Being Synthesized

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports that it has shipped FluCide™ to BASi for the start of toxicology studies.

NanoViricides Files Annual Report

NanoViricides Files Annual Report

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that it has filed its financial year end annual report (Form 10-K) with the Securities and Exchange Commission (SEC) on Monday, September 29, 2014.

NanoViricides Reports That Its CEO Dr. Seymour Will Be Interviewed About The Evolving Ebola Crisis On Fox Business News At 9PM EDT This Evening

NanoViricides Reports That Its CEO Dr. Seymour Will Be Interviewed About The Evolving Ebola Crisis On Fox Business News At 9PM EDT This Evening

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”), a nanomedicine company developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH will be a guest on “The Independents”, a...

NanoViricides Reports That It Has Designed And Commenced Synthesis Of Novel Ebola Drug Candidates; Dr. Seymour To Present At The Rodman And Renshaw Conference In New York Today

NanoViricides Reports That It Has Designed And Commenced Synthesis Of Novel Ebola Drug Candidates; Dr. Seymour To Present At The Rodman And Renshaw Conference In New York Today

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”), a nanomedicine company developing anti-viral drugs, reported further progress in its anti-Ebola drug development program.

NanoViricides Raises Approximately $7.5 Million Upon Exercise Of Certain Old Warrants By Its Long Standing Investors

NanoViricides Raises Approximately $7.5 Million Upon Exercise Of Certain Old Warrants By Its Long Standing Investors

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reported today that it has raised approximately $7.

NanoViricides To Ring Opening Bell At New York Stock Exchange

NanoViricides To Ring Opening Bell At New York Stock Exchange

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”), a nanomedicines company developing drugs that viruses would not readily escape, will ring The Opening Bell® at the New York Stock Exchange (NYSE)...

NanoViricides To Restart Its Anti-Ebola Virus Drug Development Program

NanoViricides To Restart Its Anti-Ebola Virus Drug Development Program

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports that it is restarting its drug development program to combat Ebola virus infections.

NanoViricides President Dr. Diwan Was An Invited Participant At The Prestigious CEO Roundtable

NanoViricides President Dr. Diwan Was An Invited Participant At The Prestigious CEO Roundtable

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports that its President, Dr.

NanoViricides Inc. Celebrated The Grand Opening Of Its New R&D And CGMP Pilot Manufacturing Facility With Congressman Jim Himes As The Chief Guest Yesterday

NanoViricides Inc. Celebrated The Grand Opening Of Its New R&D And CGMP Pilot Manufacturing Facility With Congressman Jim Himes As The Chief Guest Yesterday

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) celebrated the grand opening of its new R&D and cGMP pilot manufacturing facility with Congressman Jim Himes as the Chief Guest yesterday, July 21.

NanoViricides President Dr. Diwan Presented FluCide Data At The 3rd Annual Influenza Conference Held By GTC Bio On Friday, July 11

NanoViricides President Dr. Diwan Presented FluCide Data At The 3rd Annual Influenza Conference Held By GTC Bio On Friday, July 11

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports that its President, Dr.

NanoViricides Reports That Its Director Dr. Milton Boniuk, A Director, Has Invested $5M Into The Company In A Convertible Debenture

NanoViricides Reports That Its Director Dr. Milton Boniuk, A Director, Has Invested $5M Into The Company In A Convertible Debenture

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reported today that Milton Boniuk, MD, the Caroline F.

NanoViricides Reports That A Certificate Of Occupancy Has Been Issued For The New CGMP Manufacturing And R&D Facility In Shelton, CT

NanoViricides Reports That A Certificate Of Occupancy Has Been Issued For The New CGMP Manufacturing And R&D Facility In Shelton, CT

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports that the Construction Phase for its total renovation program of the facility at 1 Controls Drive, Shelton, CT is now complete.